Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival Using Parametric Modelling Methods

Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival... Oncol Ther (2017) 5:53–67 DOI 10.1007/s40487-017-0048-0 ORIGINAL RESEARCH Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival Using Parametric Modelling Methods Rebecca C. Harvey Received: April 10, 2017 / Published online: June 6, 2017 The Author(s) 2017. This article is an open access publication availability of Kaplan–Meier curves for overall ABSTRACT survival. Individual patient data (IPD) were recreated using digitisation software along with Introduction: Advanced gastric cancer (AGC) is a published algorithm in R. The data were one of the most common forms of cancer and analysed using multi-dimensional network remains difficult to cure. There is currently no meta-analysis (NMA) methods. A series of recommended therapy for second-line AGC in parametric models were fitted to the pseu- the UK despite the availability of various inter- do-IPD. Both fixed and random-effects models ventions. This paper aims to compare different were fitted to explore long-term survival pro- interventions for treatment of second-line AGC spects based on extrapolation methods and using more complex methods to estimate rela- estimated mean survival. tive efficacy, fitting various parametric models Results: Relative efficacy estimates were and to compare results to those published compared to those previously reported, which adopting conventional methods of synthesis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival Using Parametric Modelling Methods

Harvey, Rebecca
Oncology and Therapy , Volume 5 (1) – Jun 6, 2017
Download PDF
15 pages

Loading next page...
 
/lp/springer-journals/second-line-treatments-for-advanced-gastric-cancer-a-network-meta-US09JRqSXk
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-017-0048-0
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2017) 5:53–67 DOI 10.1007/s40487-017-0048-0 ORIGINAL RESEARCH Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival Using Parametric Modelling Methods Rebecca C. Harvey Received: April 10, 2017 / Published online: June 6, 2017 The Author(s) 2017. This article is an open access publication availability of Kaplan–Meier curves for overall ABSTRACT survival. Individual patient data (IPD) were recreated using digitisation software along with Introduction: Advanced gastric cancer (AGC) is a published algorithm in R. The data were one of the most common forms of cancer and analysed using multi-dimensional network remains difficult to cure. There is currently no meta-analysis (NMA) methods. A series of recommended therapy for second-line AGC in parametric models were fitted to the pseu- the UK despite the availability of various inter- do-IPD. Both fixed and random-effects models ventions. This paper aims to compare different were fitted to explore long-term survival pro- interventions for treatment of second-line AGC spects based on extrapolation methods and using more complex methods to estimate rela- estimated mean survival. tive efficacy, fitting various parametric models Results: Relative efficacy estimates were and to compare results to those published compared to those previously reported, which adopting conventional methods of synthesis.

Journal

Oncology and Therapy – Springer Journals

Published: Jun 6, 2017

References

  • Second-line treatments for advanced gastric cancer: interpreting outcomes by network meta-analysis
    Badiani, B; Maratea, D; Messori, A
  • Network meta-analysis of survival data with fractional polynomials
    Jansen, JP
  • Network meta-analysis of parametric survival curves
    Ouwens, MJNM; Philips, Z; Jansen, JP
  • Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models
    Cope, S; Ouwens, MJNM; Jansen, JP; Schmid, P
  • A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia
    Ladyzynski, P; Molik, M; Folynski, P
  • Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial
    Woods, BS; Hawkins, N; Scott, DA
  • Meta-analysis when only the median survival times are known: a comparison with individual patient data results
    Michaels, S; Piedbois, P; Burdett, S
  • The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
    Higgins, JPT; Altman, DG; Gøtzsche, PC; Juni, P; Moher, D; Oxman, AD
  • Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves
    Guyot, P; Ades, AE; Ouwens, MJNM
  • Alternative methods for monitoring convergence of iterative simulations
    Brooks, SP; Gelman, A
  • Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Thuss-Patience, PC; Kretzschmar, A; Bichev, D
  • Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial
    Hironaka, S; Ueda, S; Yasui, H
  • Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
    Ford, HE; Marshall, A; Bridgewater, JA
  • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
    Fuchs, CS; Tomasek, J; Yong, CJ
  • Salvage chemotherapy for pre-treated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone
    Kang, JH; Lee, SI; Lim, H
  • Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study
    Ohtsu, A; Ajani, JA; Bai, YX
  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    Wilke, H; Muro, K; Cutsem, E
  • Chemotherapy beyond second-line in advanced gastric cancer
    Kim, SM; Park, SH
  • Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research
    Signorovitch, JE; Sikirica, V; Erder, MH